Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.1% - What's Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) traded down 1.1% on Monday . The stock traded as low as $4.83 and last traded at $4.98. 6,843,864 shares changed hands during mid-day trading, a decline of 56% from the average session volume of 15,388,591 shares. The stock had previously closed at $5.03.

Analysts Set New Price Targets

RXRX has been the subject of a number of research analyst reports. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Morgan Stanley cut their target price on shares of Recursion Pharmaceuticals from $8.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Monday, June 16th. Needham & Company LLC decreased their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Finally, Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $7.00.

Recursion Pharmaceuticals Trading Down 3.1%

The business's 50 day moving average price is $4.92 and its two-hundred day moving average price is $6.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.11 and a current ratio of 4.11. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -2.75 and a beta of 0.84.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The firm had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. During the same quarter last year, the company earned ($0.39) earnings per share. The business's revenue for the quarter was up 7.2% on a year-over-year basis. Equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors have recently bought and sold shares of RXRX. Brighton Jones LLC boosted its holdings in Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after acquiring an additional 6,699 shares during the period. Rhumbline Advisers raised its stake in Recursion Pharmaceuticals by 7.6% during the 4th quarter. Rhumbline Advisers now owns 334,032 shares of the company's stock valued at $2,258,000 after purchasing an additional 23,564 shares during the last quarter. Atria Wealth Solutions Inc. bought a new stake in Recursion Pharmaceuticals in the 4th quarter valued at $75,000. Global Retirement Partners LLC grew its position in Recursion Pharmaceuticals by 31.5% in the 4th quarter. Global Retirement Partners LLC now owns 31,297 shares of the company's stock worth $212,000 after purchasing an additional 7,500 shares during the last quarter. Finally, Private Advisor Group LLC increased its holdings in shares of Recursion Pharmaceuticals by 103.8% during the 4th quarter. Private Advisor Group LLC now owns 31,427 shares of the company's stock worth $212,000 after purchasing an additional 16,008 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.